尼麦角林治疗血管性痴呆患者的短期成本-效果

A Short-Term Cost-Effecttiveness Analysis of Nigroxine for the Treatment of Vascular Dementia

目的探讨原研药尼麦角林与石杉碱甲治疗血管性痴呆患者的短期成本-效果。方法通过PubMed、万方数据知识服务平台、中文期刊全文数据库、中国期刊全文数据库等数据库检索已经公开发表的尼麦角林对比石杉碱甲在血管性痴呆治疗中临床疗效比较的文献,和公开的中国本土费用数据,比较短期尼麦角林对比石杉碱甲在血管性痴呆治疗中的临床疗效和成本差异。根据中国药物经济学评价指南采用最小成本分析法评价两药的经济学。结果在16周的血管性痴呆治疗中,单药使用尼麦角林对比石杉碱甲,在临床疗效上差异无统计学意义(t=0.43,P=0.668)。按照说明书推荐的两药最小剂量给药,则尼麦角林成本略低于石杉碱甲,总费用分别为366.2元和423元,即尼麦角林相比于石杉碱甲日费用节约0.51元。若根据说明书推荐两药的最大剂量给药,则尼麦角林费用略高于石杉碱甲,总费用分别为1097.60元和847.84元,即尼麦角林相比于石杉碱甲日费用增加约2.23元。结论单药使用尼麦角林对比石杉碱甲在血管性痴呆治疗中在临床疗效尚未发现明显差异,日费用方面差异随剂量变化居于节约0.51元/d至增加2.23元/d。

Objective To explore the short-term cost-effectiveness analysis of nicergoline(brand-name drug)versus Huperzine A in the treatment of patients with vascular dementia.Methods Through PubMed,Wanfang Data Knowledge Service Platform,Chinese Periodicals Full-Text Database,China Periodicals Full-Text Database and other databases,we searched for published literature on the clinical efficacy of the comparison of Nicergoline versus Huperzine A in the treatment of vascular dementia,and the published China local cost data to compare the clinical efficacy and cost difference of short-term Nicergoline versus Huperzine A in the treatment of vascular dementia.According to the Chinese Pharmacoeconomics Evaluation Guidelines,the least cost analysis method was used to evaluate the economics of the two drugs.Results In the 16-week treatment of vascular dementia,there was no statistically significant difference in clinical efficacy(t=0.43,P-value=0.668)between the single drug nicergoline and Huperzine A.According to the minimum dose of the two drugs recommended in the instructions,the cost of Nicergoline was slightly lower than that of Huperzine A,and the total cost was 366.2 yuan and 423 yuan,respectively.That is,Nicergoline saved 0.51 yuan per day compared with Huperzine A.If the maximum dose of the two drugs was recommended according to the instructions,the cost of Nicergoline was slightly higher than that of Huperzine A.The total cost was RMB 1,097.60 and RMB 847.84,respectively.That is,the cost of Nicergoline increased by 2.23 yuan per day,compared with Huperzine A.Conclusion Nicergoline compared with Huperzine A in the treatment of vascular dementia has not yet found a significant difference in clinical efficacy.The difference in daily cost varies with the dose,from saving 0.51 yuan/d to increasing 2.23 yuan/d.